New Two-Pronged attack on tough breast cancer enters testing

This study aims to see if adding a new two-drug immunotherapy combination (iparomlimab and tuvonralimab) to standard platinum chemotherapy works better than chemotherapy alone for controlling advanced triple-negative breast cancer that has worsened after initial treatments. It will involve 78 adults whose cancer has spread and who have already tried one or two prior treatments. Participants will be randomly assigned to receive either the new drug combo with chemo or just chemo, and doctors will track how long the cancer is kept from growing.